May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- AI boosts accuracy in surgical reports, outperforming surgeons
- AI models improve prediction of surgical complications using preoperative clinical notes
- Ambient AI healthcare documentation gains traction as capabilities expand
- Healthcare M&A faces tighter review as FTC retains guidelines
- Healthcare giants prioritize shareholder payouts over patient care
- Texas abortion ban linked to spike in pregnancy complications, maternal death
- AI streamlines documentation, frees time for nurses at Cedars-Sinai surgical unit
- Study identifies potential non-surgical treatment for inguinal hernias
- Rural hospital closures remain a growing concern despite slight financial improvement
- Session: Hoisting the Sails—Winning Strategies for Growing Service Lines in an ASC
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement